Cosmo Pharmaceuticals N.V (C43) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) has a cash flow conversion efficiency ratio of 0.013x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€6.28 Million ≈ $7.35 Million USD) by net assets (€469.22 Million ≈ $548.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cosmo Pharmaceuticals N.V - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Cosmo Pharmaceuticals N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cosmo Pharmaceuticals N.V (C43) financial obligations for a breakdown of total debt and financial obligations.
Cosmo Pharmaceuticals N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eco World Develop Group
KLSE:8206
|
0.031x |
|
PT Arkora Hydro Tbk
JK:ARKO
|
-0.153x |
|
S&T Bancorp Inc
NASDAQ:STBA
|
0.028x |
|
Sobha Limited
NSE:SOBHA
|
0.063x |
|
Almonty Industries Inc. Common Shares
NASDAQ:ALM
|
0.063x |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
0.012x |
|
Greif Bros Corporation
NYSE:GEF
|
-0.008x |
|
PLUXEE NV
PA:PLX
|
0.434x |
Annual Cash Flow Conversion Efficiency for Cosmo Pharmaceuticals N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of Cosmo Pharmaceuticals N.V from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Cosmo Pharmaceuticals N.V.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €489.18 Million ≈ $571.90 Million |
€-12.48 Million ≈ $-14.60 Million |
-0.026x | -107.94% |
| 2024-12-31 | €505.09 Million ≈ $590.50 Million |
€162.41 Million ≈ $189.88 Million |
0.322x | +286.00% |
| 2023-12-31 | €403.62 Million ≈ $471.88 Million |
€33.62 Million ≈ $39.31 Million |
0.083x | +16.28% |
| 2022-12-31 | €463.79 Million ≈ $542.22 Million |
€33.23 Million ≈ $38.84 Million |
0.072x | +191.24% |
| 2021-12-31 | €512.68 Million ≈ $599.37 Million |
€12.61 Million ≈ $14.74 Million |
0.025x | -24.20% |
| 2020-12-31 | €400.12 Million ≈ $467.79 Million |
€12.98 Million ≈ $15.18 Million |
0.032x | +167.80% |
| 2019-12-31 | €393.73 Million ≈ $460.32 Million |
€-18.85 Million ≈ $-22.03 Million |
-0.048x | -109.50% |
| 2018-12-31 | €444.85 Million ≈ $520.08 Million |
€-10.16 Million ≈ $-11.88 Million |
-0.023x | -13.93% |
| 2017-12-31 | €470.12 Million ≈ $549.62 Million |
€-9.43 Million ≈ $-11.02 Million |
-0.020x | -138.42% |
| 2016-12-31 | €415.56 Million ≈ $485.83 Million |
€21.69 Million ≈ $25.36 Million |
0.052x | -- |
About Cosmo Pharmaceuticals N.V
Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris;… Read more